On July 26, 2016 Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) reported its consolidated financial results for the first quarter ended June 30, 2016 under International Financial Reporting Standards (IFRS) (Press release, Dr Reddy’s, JUL 26, 2016, View Source [SID:1234514050]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Q1 FY17: Key Highlights
Consolidated revenues at Rs. 32.3 billion, year-on-year decline of 14%
Gross Profit Margin at 56.2%, declined by ~490 bps over that of last year
Research & Development (R&D) spend at Rs. 4.8 billion, year-on-year increase of 9%. Continued focus on building complex generics and differentiated products pipeline
Selling, general & administrative (SG&A) expenses at Rs. 12.3 billion, year-on-year increase of 12%
EBITDA at Rs. 4.0 billion, 12.3% of revenues
Profit after tax at Rs. 1.3 billion, 3.9% of revenues
Co-chairman and CEO GV Prasad said: "We have come through a very difficult first quarter, with our top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela. We also faced a number of challenges in the quarter including price erosion and delayed launches as a result of the warning letter, which significantly impacted our earnings. However, we continue to take actions that focus on remediation, strengthening our quality systems and executing on our strong product pipeline. We remain focused on generating long term, sustainable growth."
All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of I USD = Rs. 67.51
Dr. Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income Statement
Particulars Q1 FY 17 Q1 FY 16
Growth %
($) (Rs.) % ($) (Rs.) %
Revenues 479 32,345 100.0 557 37,578 100.0 (14)
Cost of revenues 210 14,167 43.8 217 14,631 38.9 (3)
Gross profit 269 18,178 56.2 340 22,947 61.1 (21)
Operating Expenses
Selling, general & administrative expenses 182 12,284 38.0 163 10,973 29.2 12
Research and development expenses 71 4,802 14.8 65 4,387 11.7 9
Other operating expense / (income) (1) (96) (0.3) (2) (125) (0.3) (23)
Results from operating activities 18 1,188 3.7 114 7,712 20.5 (85)
Finance expense / (income), net (7) (445) (1.4) (3) (216) (0.6) 106
Share of (profit) of equity accounted investees, net of income tax (1) (74) (0.2) (1) (49) (0.1) 49
Profit before income tax 25 1,707 5.3 118 7,977 21.2 (79)
Income tax expense 7 444 1.4 25 1,720 4.6 (74)
Profit for the period 19 1,263 3.9 93 6,257 16.6 (80)
Diluted EPS 0.11 7.43 0.54 36.58 (80)
EBITDA Computation
Particulars Q1 FY 17 Q1 FY 16
($) (Rs.) ($) (Rs.)
Profit before tax 25 1,707 118 7,977
Interest (income) / expense net* (6) (409) (5) (304)
Depreciation 26 1,760 23 1,519
Amortization 14 921 11 749
EBITDA 59 3,979 147 9,941
EBITDA (% to sales) 12.3 26.5
* Includes income from investments
All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of I USD = Rs. 67.51
Key Balance Sheet Items
Particulars As on 30th June 16 As on 31st March 16
($) (Rs.) ($) (Rs.)
Cash and cash equivalents and Other current Investments 379 25,578 592 39,955
Trade receivables 526 35,499 612 41,306
Inventories 414 27,922 379 25,578
Property, plant and equipment 814 54,951 799 53,961
Goodwill and Other Intangible assets 419 28,284 365 24,644
Loans and borrowings (current & non-current) 557 37,632 496 33,513
Trade payables 188 12,723 182 12,300
Equity 1,690 1,14,112 1,901 1,28,336
Revenue Mix by Segment
Particulars Q1 FY 17
Q1 FY 16
Growth %
($) (Rs.) % ($) (Rs.) %
Global Generics 395 26,638 82 459 30,961 82 (14)
North America 15,523 18,516 (16)
Europe* 1,615 1,912 (16)
India 5,223 4,756 10
Emerging Markets# 4,277 5,777 (26)
PSAI 70 4,692 15 83 5,614 15 (16)
North America 643 580 11
Europe 1,947 2,350 (17)
India 372 670 (44)
Rest of World 1,730 2,014 (14)
Proprietary Products & Others 15 1,015 3 15 1,003 3 1
Total 479 32,345 100 557 37,578 100 (14)
* Europe primarily includes Germany, UK and out licensing sales business
# Emerging Markets refers to Russia, other CIS countries, Romania and Rest of the World markets including Venezuela.
Segmental Analysis
Global Generics
Revenues from Global Generics segment are at Rs. 26.6 billion, year-on-year decline of 14%; decline primarily on account of lower contribution from North America and loss of sales from Venezuela.
Revenues from North America at Rs. 15.5 billion, year-on-year decline of 16%. Decline primarily on account of increased competition primarily in valgancyclovir and azacitidine, coupled with pricing pressure and moderation in volumes off-take.
As of 30th June, 2016, cumulatively 78 generic filings are pending for approval with the USFDA (76 ANDAs and 2 NDAs under 505(b)(2) route). Of these 76 ANDAs, 50 are Para IVs out of which we believe 18 have ‘First to File’ status.
Revenues from Emerging Markets at Rs. 4.3 billion, year-on-year decline of 26%.
Revenues from Russia at Rs. 2.3 billion, year-on-year growth of 2%. Moderate growth primarily on account of depreciation of Ruble, in constant currency revenues grew by 23% year-on-year. Sequentially, the revenues have been stable.
Revenues from other CIS countries and Romania market at Rs. 0.7 billion, year-on-year decline of 15%.
Revenues from Rest of World (RoW) territories at Rs. 1.3 billion, year-on-year decline of 53% primarily on account of no sales in Venezuela. Ex-Venezuela it grew by 19%.
Revenues from India at Rs. 5.2 billion, year-on-year growth of 10%. NPPA pricing notifications and the WPI based annual price decline impacted growth. Portfolio acquired from UCB well-integrated into our supply chain.
Revenues from Europe at Rs. 1.6 billion, year-on-year decline of 16%.
Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI at Rs. 4.7 billion, year-on-year decline of 16%. Decline primarily on account of lower dispatches in API business on account of the ongoing remediation activities.
During the quarter, 19 DMFs were filed globally of which 2 were in the US. The cumulative number of DMF filings as of 30th June, 2016 was 784.
Proprietary Products (PP)
Subsequent to the approvals received from USFDA for 2 NDAs, the company had launched these two molecules ZembraceSym Touch (Suma 3 mg) injection and Sernivo (betamethasone dipropionate) Spray, 0.05% in the US. The performance of these two molecules is gradually picking up traction.
Income Statement Highlights:
Gross profit margin at 56.2% and declined by ~490 bps over that of previous year primarily led by increased competitive intensity in some of the key products in NAG and relatively lower price realizations. Gross profit margin for Global Generics (GG) and PSAI business segments are at 61.3% and 24.1% respectively.
SG&A expenses at Rs. 12.3 billion, year-on-year growth of 12%. This increase is largely due to the ongoing remediation activities, launch related activities for the approved NDAs by PP and certain routine items related to manpower and other spends.
Research & development expenses at Rs. 4.8 billion, year-on-year growth of 9%. As a % to sales R&D expenses stood at 14.8% in Q1 FY17 as compared to 11.7% in Q1 FY16. Continued focus on building complex generics and differentiated products pipeline.
Net Finance income at Rs. 445 million compared to the net finance income of Rs. 216 million in Q1 FY16. The incremental charge of Rs. 229 million is on account of:
Net foreign exchange gain of Rs. 36 million in the current quarter vs net foreign exchange loss of Rs. 88 million in the previous year.
Increase in profit on sales of investments by Rs. 54 million.
Net increase in interest income of Rs. 51 million.
Profit after Tax at Rs. 1.3 billion
Diluted earnings per share is at Rs. 7.4
Capital expenditure is at Rs. 3.2 billion.
Earnings Call Details (06.30 pm IST, July 26, 2016)